Pancreatic Cancer Research

ResearcherMoffitt Cancer CenterNo recent work listed

Ravi Shridhar

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0799-4074; OpenAlex author ID A5029626497. Sources: OpenAlex.

Their work

Papers
20 (first author 3, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
39
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: 3 papers · 2015: 5 papers · 2016: 4 papers · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 1 paper

Papers 20

  1. Adjuvant therapy for margin positive pancreatic cancer: A propensity score matched analysis. First author DOI 10.1016/j.pan.2022.03.008↗
  2. Multi-agent neoadjuvant chemotherapy improves response and survival in patients with resectable pancreatic cancer. First author DOI 10.21037/jgo.2019.12.03↗
  3. Neoadjuvant therapy and pancreatic cancer: a national cancer database analysis. Co-author DOI 10.21037/jgo.2019.02.09↗
  4. Correlation of tumor size and survival in pancreatic cancer. First author DOI 10.21037/jgo.2018.08.06↗
  5. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy… Co-author DOI 10.1080/0284186x.2016.1256497↗
  6. Outcomes of adjuvant radiotherapy and lymph node resection in elderly patients with pancreatic cancer treated with surgery and chemotherapy. Co-author DOI 10.21037/jgo.2017.08.05↗
  7. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Co-author DOI 10.1016/s1470-2045(16)00172-8↗
  8. Outcomes of a Clinical Pathway for Borderline Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-015-5006-1↗
  9. Favorable perioperative outcomes after resection of borderline resectable pancreatic cancer treated with neoadjuvant stereotactic radiation and chemotherapy co… Last author DOI 10.21037/jgo.2016.03.15↗
  10. Histopathologic tumor response after induction chemotherapy and stereotactic body radiation therapy for borderline resectable pancreatic cancer. Co-author DOI 10.3978/j.issn.2078-6891.2015.075↗
  11. Comparative long-term outcomes of upfront resected pancreatic cancer after preoperative biliary drainage. Last author DOI 10.1007/s00464-015-4075-3↗
  12. Resected pancreatic cancer outcomes in the elderly. Last author DOI 10.1016/j.jgo.2014.11.005↗
  13. Radiosensitivity index predicts for survival with adjuvant radiation in resectable pancreatic cancer. Last author DOI 10.1016/j.radonc.2015.07.018↗
  14. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarc… Last author DOI 10.3109/0284186x.2015.1004367↗
  15. Outcomes of resected pancreatic cancer in patients age ≥70. Last author DOI 10.3978/j.issn.2078-6891.2015.038↗
  16. Adjuvant radiotherapy and lymph node dissection in pancreatic cancer treated with surgery and chemotherapy. Last author DOI 10.1002/cncr.28543↗
  17. Neoadjuvant vs adjuvant therapy for resectable pancreatic cancer: the evolving role of radiation. Last author DOI 10.1016/j.semradonc.2013.11.002↗
  18. Adjuvant radiotherapy and lymph node status for pancreatic cancer: results of a study from the Surveillance, Epidemiology, and End Results (SEER) Registry Data. Co-author DOI 10.1097/coc.0b013e31826e0570↗
  19. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Last author DOI 10.1016/j.ijrobp.2013.02.022↗
  20. Comparison of 1-, 2-, and 3-Dimensional Tumor Response Assessment After Neoadjuvant GTX-RT in Borderline-Resectable Pancreatic Cancer. Co-author PMID 22368736↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kenneth Lee Meredith · 9 shared papers, 2013–2022 · strength 0.87
  2. Sarah E. Hoffe · 14 shared papers, 2011–2017 · strength 0.72
  3. Gregory M. Springett · 13 shared papers, 2011–2017 · strength 0.65
  4. Mokenge Peter Malafa · 13 shared papers, 2011–2017 · strength 0.65
  5. Pamela Joy Hodul · 12 shared papers, 2011–2017 · strength 0.60
  6. Caitlin Takahashi · 3 shared papers, 2018–2022 · strength 0.48
  7. Eric A. Mellon · 8 shared papers, 2013–2017 · strength 0.42
  8. Jessica M. Frakes · 7 shared papers, 2015–2017 · strength 0.40
  9. Tobin Joel Crill Strom · 7 shared papers, 2015–2017 · strength 0.38
  10. Michael David Chuong · 5 shared papers, 2011–2016 · strength 0.23
  11. Barbara Ann Centeno · 3 shared papers, 2016–2017 · strength 0.17
  12. Paige A. Blinn · 1 shared paper, 2020 · strength 0.15
  13. William H. Jin · 1 shared paper, 2017 · strength 0.07
  14. Krisha J. Opfermann · 1 shared paper, 2014 · strength 0.05
  15. David T. Marshall · 1 shared paper, 2014 · strength 0.05
  16. Thomas J. Hayman · 1 shared paper, 2015 · strength 0.05
  17. Jason B. Klapman · 1 shared paper, 2015 · strength 0.05
  18. Dung‐Tsa Chen · 1 shared paper, 2016 · strength 0.05
  19. José M. Pimiento · 1 shared paper, 2016 · strength 0.05
  20. Omar Maen Rashid · 1 shared paper, 2016 · strength 0.05
  21. Domenico Coppola · 1 shared paper, 2015 · strength 0.05
  22. Theodore Sunki Hong · 1 shared paper, 2016 · strength 0.04
  23. Jason Edward Faris · 1 shared paper, 2016 · strength 0.04
  24. Florian Hohla · 1 shared paper, 2016 · strength 0.04
  25. Thierry Conroy · 1 shared paper, 2016 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.